Cargando…

Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs

OBJECTIVE: The worldwide prevalence of obesity has increased to 10% in men and 15% in women and is associated with severe comorbidities such as diabetes, cancer, and cardiovascular disease. Animal models of obesity are central to experimental studies of disease mechanisms and therapeutic strategies....

Descripción completa

Detalles Bibliográficos
Autores principales: Renner, Simone, Blutke, Andreas, Dobenecker, Britta, Dhom, Georg, Müller, Timo D., Finan, Brian, Clemmensen, Christoffer, Bernau, Maren, Novak, Istvan, Rathkolb, Birgit, Senf, Steffanie, Zöls, Susanne, Roth, Mirjam, Götz, Anna, Hofmann, Susanna M., Hrabĕ de Angelis, Martin, Wanke, Rüdiger, Kienzle, Ellen, Scholz, Armin M., DiMarchi, Richard, Ritzmann, Mathias, Tschöp, Matthias H., Wolf, Eckhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157610/
https://www.ncbi.nlm.nih.gov/pubmed/30017782
http://dx.doi.org/10.1016/j.molmet.2018.06.015
_version_ 1783358295218585600
author Renner, Simone
Blutke, Andreas
Dobenecker, Britta
Dhom, Georg
Müller, Timo D.
Finan, Brian
Clemmensen, Christoffer
Bernau, Maren
Novak, Istvan
Rathkolb, Birgit
Senf, Steffanie
Zöls, Susanne
Roth, Mirjam
Götz, Anna
Hofmann, Susanna M.
Hrabĕ de Angelis, Martin
Wanke, Rüdiger
Kienzle, Ellen
Scholz, Armin M.
DiMarchi, Richard
Ritzmann, Mathias
Tschöp, Matthias H.
Wolf, Eckhard
author_facet Renner, Simone
Blutke, Andreas
Dobenecker, Britta
Dhom, Georg
Müller, Timo D.
Finan, Brian
Clemmensen, Christoffer
Bernau, Maren
Novak, Istvan
Rathkolb, Birgit
Senf, Steffanie
Zöls, Susanne
Roth, Mirjam
Götz, Anna
Hofmann, Susanna M.
Hrabĕ de Angelis, Martin
Wanke, Rüdiger
Kienzle, Ellen
Scholz, Armin M.
DiMarchi, Richard
Ritzmann, Mathias
Tschöp, Matthias H.
Wolf, Eckhard
author_sort Renner, Simone
collection PubMed
description OBJECTIVE: The worldwide prevalence of obesity has increased to 10% in men and 15% in women and is associated with severe comorbidities such as diabetes, cancer, and cardiovascular disease. Animal models of obesity are central to experimental studies of disease mechanisms and therapeutic strategies. Diet-induced obesity (DIO) models in rodents have provided important insights into the pathophysiology of obesity and, in most instances, are the first in line for exploratory pharmacology studies. To deepen the relevance towards translation to human patients, we established a corresponding DIO model in Göttingen minipigs (GM). METHODS: Young adult female ovariectomized GM were fed a high-fat/high-energy diet for a period of 70 weeks. The ration was calculated to meet the requirements and maintain body weight (BW) of lean adult minipigs (L-GM group) or increased stepwise to achieve an obese state (DIO-GM group). Body composition, blood parameters and intravenous glucose tolerance were determined at regular intervals. A pilot chronic treatment trial with a GLP1 receptor agonist was conducted in DIO-GM. At the end of the study, the animals were necropsied and a biobank of selected tissues was established. RESULTS: DIO-GM developed severe subcutaneous and visceral adiposity (body fat >50% of body mass vs. 22% in L-GM), increased plasma cholesterol, triglyceride, and free fatty acid levels, insulin resistance (HOMA-IR >5 vs. 2 in L-GM), impaired glucose tolerance and increased heart rate when resting and active. However, fasting glucose concentrations stayed within normal range throughout the study. Treatment with a long-acting GLP1 receptor agonist revealed substantial reduction of food intake and body weight within four weeks, with increased drug sensitivity relative to observations in other DIO animal models. Extensive adipose tissue inflammation and adipocyte necrosis was observed in visceral, but not subcutaneous, adipose tissue of DIO-GM. CONCLUSIONS: The Munich DIO-GM model resembles hallmarks of the human metabolic syndrome with extensive adipose tissue inflammation and adipocyte necrosis reported for the first time. DIO-GM may be used for evaluating novel treatments of obesity and associated comorbidities. They may help to identify triggers and mechanisms of fat tissue inflammation and mechanisms preventing complete metabolic decompensation despite morbid obesity.
format Online
Article
Text
id pubmed-6157610
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61576102018-09-27 Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs Renner, Simone Blutke, Andreas Dobenecker, Britta Dhom, Georg Müller, Timo D. Finan, Brian Clemmensen, Christoffer Bernau, Maren Novak, Istvan Rathkolb, Birgit Senf, Steffanie Zöls, Susanne Roth, Mirjam Götz, Anna Hofmann, Susanna M. Hrabĕ de Angelis, Martin Wanke, Rüdiger Kienzle, Ellen Scholz, Armin M. DiMarchi, Richard Ritzmann, Mathias Tschöp, Matthias H. Wolf, Eckhard Mol Metab Brief Communication OBJECTIVE: The worldwide prevalence of obesity has increased to 10% in men and 15% in women and is associated with severe comorbidities such as diabetes, cancer, and cardiovascular disease. Animal models of obesity are central to experimental studies of disease mechanisms and therapeutic strategies. Diet-induced obesity (DIO) models in rodents have provided important insights into the pathophysiology of obesity and, in most instances, are the first in line for exploratory pharmacology studies. To deepen the relevance towards translation to human patients, we established a corresponding DIO model in Göttingen minipigs (GM). METHODS: Young adult female ovariectomized GM were fed a high-fat/high-energy diet for a period of 70 weeks. The ration was calculated to meet the requirements and maintain body weight (BW) of lean adult minipigs (L-GM group) or increased stepwise to achieve an obese state (DIO-GM group). Body composition, blood parameters and intravenous glucose tolerance were determined at regular intervals. A pilot chronic treatment trial with a GLP1 receptor agonist was conducted in DIO-GM. At the end of the study, the animals were necropsied and a biobank of selected tissues was established. RESULTS: DIO-GM developed severe subcutaneous and visceral adiposity (body fat >50% of body mass vs. 22% in L-GM), increased plasma cholesterol, triglyceride, and free fatty acid levels, insulin resistance (HOMA-IR >5 vs. 2 in L-GM), impaired glucose tolerance and increased heart rate when resting and active. However, fasting glucose concentrations stayed within normal range throughout the study. Treatment with a long-acting GLP1 receptor agonist revealed substantial reduction of food intake and body weight within four weeks, with increased drug sensitivity relative to observations in other DIO animal models. Extensive adipose tissue inflammation and adipocyte necrosis was observed in visceral, but not subcutaneous, adipose tissue of DIO-GM. CONCLUSIONS: The Munich DIO-GM model resembles hallmarks of the human metabolic syndrome with extensive adipose tissue inflammation and adipocyte necrosis reported for the first time. DIO-GM may be used for evaluating novel treatments of obesity and associated comorbidities. They may help to identify triggers and mechanisms of fat tissue inflammation and mechanisms preventing complete metabolic decompensation despite morbid obesity. Elsevier 2018-06-28 /pmc/articles/PMC6157610/ /pubmed/30017782 http://dx.doi.org/10.1016/j.molmet.2018.06.015 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Communication
Renner, Simone
Blutke, Andreas
Dobenecker, Britta
Dhom, Georg
Müller, Timo D.
Finan, Brian
Clemmensen, Christoffer
Bernau, Maren
Novak, Istvan
Rathkolb, Birgit
Senf, Steffanie
Zöls, Susanne
Roth, Mirjam
Götz, Anna
Hofmann, Susanna M.
Hrabĕ de Angelis, Martin
Wanke, Rüdiger
Kienzle, Ellen
Scholz, Armin M.
DiMarchi, Richard
Ritzmann, Mathias
Tschöp, Matthias H.
Wolf, Eckhard
Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title_full Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title_fullStr Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title_full_unstemmed Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title_short Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs
title_sort metabolic syndrome and extensive adipose tissue inflammation in morbidly obese göttingen minipigs
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157610/
https://www.ncbi.nlm.nih.gov/pubmed/30017782
http://dx.doi.org/10.1016/j.molmet.2018.06.015
work_keys_str_mv AT rennersimone metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT blutkeandreas metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT dobeneckerbritta metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT dhomgeorg metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT mullertimod metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT finanbrian metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT clemmensenchristoffer metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT bernaumaren metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT novakistvan metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT rathkolbbirgit metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT senfsteffanie metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT zolssusanne metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT rothmirjam metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT gotzanna metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT hofmannsusannam metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT hrabedeangelismartin metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT wankerudiger metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT kienzleellen metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT scholzarminm metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT dimarchirichard metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT ritzmannmathias metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT tschopmatthiash metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs
AT wolfeckhard metabolicsyndromeandextensiveadiposetissueinflammationinmorbidlyobesegottingenminipigs